Board of Directors
Omid Farokhzad
Omid Farokhzad
Chair & Chief Executive Officer
Meeta Gulyani
Meeta Gulyani
Head of Strategy, Business Development and Transformation at Millipore Sigma
David Hallal
David Hallal
Former Chief Executive Officer at Alexion Pharmaceuticals
Rachel Haurwitz, Ph.D.
Rachel Haurwitz, Ph.D.
CEO at Caribou Biosciences, Inc.
Robert Langer, Sc.D.
Robert Langer, Sc.D.
Co-Chairman of Scientific Advisory Board
Terry McGuire
Terry McGuire
Founding Partner of Polaris Partners
Deep Nishar
Deep Nishar
Partner at General Catalyst
Committee Composition
Director Name | Audit Committee | Corporate Governance and Nominating Committee | Science and Technology Committee | Talent and Compensation Committee |
---|---|---|---|---|
Meeta Gulyani | Chairperson of the Audit Committee | |||
David Hallal Independent Director | Chairperson of the Corporate Governance and Nominating Committee | Member of the Talent and Compensation Committee | ||
Rachel Haurwitz, Ph.D. | Member of the Audit Committee | Member of the Science and Technology Committee | Member of the Talent and Compensation Committee | |
Robert Langer, Sc.D. | Chairperson of the Science and Technology Committee | |||
Terry McGuire | Member of the Audit Committee | Chairperson of the Talent and Compensation Committee | ||
Deep Nishar | Member of the Corporate Governance and Nominating Committee | Member of the Science and Technology Committee |
- Independent Director
- Chairperson
- Member
Clinical & Scientific Advisors
Robert Langer, Sc.D.
Robert Langer, Sc.D.
Co-Chairman of Scientific Advisory Board
Steven Carr, Ph.D.
Steven Carr, Ph.D.
Senior Director of Proteomics at the Broad Institute of MIT and Harvard
Vivek Farias, Ph.D.
Vivek Farias, Ph.D.
Chair of Data Committee
Charles Cantor, Ph.D.
Charles Cantor, Ph.D.
Emeritus Professor at Boston University
Jennifer Van Eyk, Ph.D.
Jennifer Van Eyk, Ph.D.
Erika Glazer Chair in Women's Heart Health, Director of Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences, Director of Basic Science Research in the Women's Heart Center, Professor in Medicine and in Biomedical Sciences at Ce
Josh Coon, Ph.D.
Josh Coon, Ph.D.
Chair of Proteomics Committee
Luis Diaz, M.D.
Luis Diaz, M.D.
Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering
Chris Mason, Ph.D.
Chris Mason, Ph.D.
Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine; Director of the WorldQuant Initiative for Quantitative Prediction
Dr. Chris Mason is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and Director of the WorldQuant Initiative for Quantitative Prediction. His laboratory creates and deploys new genomics technologies and predictive algorithms for medicine, which helps to ameliorate human disease and lays the foundation for long-term human survival on other planets. Dr. Mason’s work spans >300 peer-reviewed papers, five patents, five diagnostics tests, and the foundation of 10 biotechnology companies and 3 non-profits. Dr. Mason also holds affiliate faculty appointments at the New York Genome Center, Yale Law School, and the Consortium for Space Genetics at Harvard Medical School. He is the author of The Next 500 Years: Engineering Life to Reach New Worlds.
Mark McClellan, Ph.D., M.D.
Mark McClellan, Ph.D., M.D.
Founding Director of the Duke-Margolis Center for Health Policy
Bruce Wilcox, Ph.D.
Bruce Wilcox, Ph.D.
Chief Technology Officer at PrognomiQ
Governance
The Board of Directors of Seer, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.